Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Clinical trial NCT02504372 · COMPLETED
Trial details
- NCT number
- NCT02504372
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-06
- Primary completion
- 2023-01-24
- Enrollment
- 1177
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.